Louis, E., Resche-Rigon, M., Laharie, D., Satsangi, J., Ding, N., Siegmund, B., D'Haens, G., Picon, L., Bossuyt, P., Vuitton, L., Irving, P., Viennot, S., Lamb, C. A., Pollok, R., Baert, F., Nachury, M., Fumery, M., Gilletta, C., Almer, S., Ben-Horin, S., Bouhnik, Y., Colombel, J., Hertervig, E., , , Andrews, J., Sparrow, M., Leong, R., Connor, S., Radforth-Smith, G., De Cruz, P., Preiss, J., Stallmach, A., Liceni, T., Grip, O., Halfvarson, J., Durai, D., Cummings, F., Seilinger, C., Parkes, M., Lindsay, J., Lambrecht, G., Van Hootegem, P., Rahier, J., Dewitte, M., Hebuterne, X., Chanteloup, E., Altwegg, R., Nancey, S., Bouguen, G., Pineton de Chambrun, G., Poullenot, F., & Roblin, X. (2023). withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. Lancet gastroenterology and hepatology, 8, 215–227. http://access.bl.uk/ark:/81055/vdc_100177563111.0x000002